Discount-store chain Dollar General (DG) saw third-quarter earnings jump 35.5% to $1.26 per share in line with analyst estimates. Net sales jumped 8.7% to $6.4 billion on a 2.8% rise in same-store sales, according to the results posted on Tuesday before the bell.
In the quarter, Dollar General board of directors declared a cash dividend of $0.29 per share.
Majority of the analysts recommend a “strong buy” or “buy” rating on the stock with an average price target of $117.75.
Operating profit for the third quarter of 2018 grew 5.9% to $442.1 million. The effective income tax rate in the third quarter of 2018 was 20.0% compared to 35.8% in the third quarter of 2017. As of November 2, 2018, total merchandise inventories, at cost, were $3.98 billion compared to $3.60 billion as of November 3, 2017, an increase of approximately 4.0% on a per store basis.
“As a result of the third quarter hurricanes and other disasters, we will record greater-than-anticipated expenses in the second half of 2018,” said John Garratt, Dollar General’s CFO. “In total, the impact to third quarter EPS was an estimated $0.05 per diluted share and we expect to see an additional estimated $0.04 impact on our fourth quarter diluted EPS. We have adjusted our full-year outlook to reflect the estimated $0.09 impact of these events, ongoing transportation cost pressures and year-to-date results, ” he added.
For fiscal 2018, Dollar General expects net sales growth to be about 9%, generating diluted EPS of $5.85-$6.05; and a cash benefit of approximately $300 million as a result of the TCJA.
The company also expects share repurchases for the fiscal year to be a minimum of $850 million, with Capex of $725-$775 million.
Get access to timely and accurate verbatim transcripts that are published within hours of the event
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on